This week the U.S. Labor Department issued new regulations that mandate your financial advisor to conform to a “fiduciary standard” when recommending investment products for retirement plans.Unlike the previous standard of “suitability”, which only required that a recommended product not be inappropriate for a client, a fiduciary level of… Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
Only three weeks ago we noted that the exoskeleton industry had made a number of significant advancements recently (“A Step in the Right Direction“). Since then one of our three exoskeleton stocks, Ekso Bionics (EKSO), got another big boost when it announced earlier this week that it received FDA… Read More
Only three weeks ago we noted that the exoskeleton industry had made a number of significant advancements recently (“A Step in the Right Direction“). Since then one of our three exoskeleton stocks, Ekso Bionics (EKSO), got another big boost when it announced earlier this week that it received FDA… Read More
The Fed is getting smarter, cars are getting smarter, and we're getting smarter (and richer!) right along with them. Read More
The Fed is getting smarter, cars are getting smarter, and we're getting smarter (and richer!) right along with them. Read More
Special Situations Portfolio Update – Argos TherapeuticsFor those of you participating in our current cancer treatment play (“One Little Shot to Kill Cancer Dead“), tomorrow is an important day. One of the three stocks we recommend in that bundle – Argos Therapeutics (ARGS) – is releasing its fourth quarter… Read More
Special Situations Portfolio Update – Argos TherapeuticsFor those of you participating in our current cancer treatment play (“One Little Shot to Kill Cancer Dead“), tomorrow is an important day. One of the three stocks we recommend in that bundle – Argos Therapeutics (ARGS) – is releasing its fourth quarter… Read More
After trying privately to convince Yahoo’s board of directors to pursue a new strategic direction for more than a year, this week hedge fund investor Starboard Value went public with its plan to oust the entire board and replace it with one of its choosing. Read More
- March 21, 2016
-
Download Issue
As we pivot into the next major long term economic cycle, the stock market is searching for a new set of companies to lead it higher and we believe it is companies such as these that will do it. Read More
As we pivot into the next major long term economic cycle, the stock market is searching for a new set of companies to lead it higher and we believe it is companies such as these that will do it. Read More